TSX VENTURE COMPANIES
BULLETIN V2026-3456
VIMY PHARMACEUTICALS CORP. ("VIMY")
[formerly, Harmony Acquisitions Corp. ("MONY.P")]
BULLETIN TYPE: Qualifying Transaction-Completed/New Symbol; Name Change and Consolidation, Resume Trading
BULLETIN DATE: November 13, 2026
TSX Venture Tier 2 Company
TSX Venture Exchange has accepted for filing the Qualifying Transaction (the "Transaction") of Vimy Pharmaceuticals Corp. (formerly, Harmony Acquisitions Corp.) (the "Company") described in its filing statement dated November 6, 2026 (the "Filing Statement").
As a result, at the opening on November 17, 2026, Vimy Pharmaceuticals Corp. will no longer be considered as a Capital Pool Company.
The Qualifying Transaction consisted of the arm's length acquisition of all of the issued and outstanding common shares in the capital of Vimy Pharmaceuticals Inc. ("Vimy Pharma") pursuant to the acquisition agreement dated September 28, 2026, (the "Acquisition Agreement") in exchange for 27,168,142 post-consolidated shares (see below) at a deemed value of $3.00 per share for aggregate gross proceeds of $81,504,426.
The Company consolidated its shares on a 1 new for 49.6 old share basis. The shares will be exchanged on a 1 for 1 basis on a post consolidated basis.
For additional information refer to the Company's press releases dated September 28, 2026, and November 12, 2026 and its Filing Statement dated November 6, 2026 which is filed on SEDAR+.
In connection with the closing of the Transaction, Vimy Pharma closed its previously announced brokered concurrent financing (the "Vimy Concurrent Financing") of $14,539,062.
A non-arm's length Finder's fee totaling 208,333 shares has been paid related to the Transaction.
Name Change and Consolidation
Pursuant to a resolution passed by shareholders on October 19, 2026, the Company has consolidated its capital on a (49.6104) old for (1) new basis. The name of the Company has also been changed as detailed below.
Effective at the opening November 17, 2026, the common shares of Vimy Pharmaceuticals Corp. will commence trading on TSX Venture Exchange, and the common shares of Harmony Acquisitions Corp. will be delisted.
Resume Trading
Effective at the opening of business on November 17, 2026, the Common Shares of Vimy Pharmaceuticals Corp. will commence trading on the TSX Venture Exchange as a Tier 2 Life Sciences company. The NAICS number of the company is 325410.
Capitalization: Unlimited number of Common Shares with no par value of which 32,347,829 Common Shares are issued and outstanding.
Escrow: 22,535,642
Transfer Agent: Odyssey Trust Company
Trading Symbol: VIMY (NEW)
CUSIP Number: 918236100 (NEW)
The Exchange has been advised that the above transactions have been completed.
Company Contact: Ben Hosein
Company Address: 2 Bloor Street West, Suite 2002, Toronto, Ontario
Company Phone Number: +1 416-554-8412
Company e-mail address: IR@vimypharma.com
Company website address: https://www.vimypharma.com/
_______________________________________
|
|
